Maham Fatima
Tue, January 27, 2026 astatine 7:38 AM CST 2 min read
On the aforesaid day, RBC Capital reduced its terms people for Alnylam to $465 from $500 portion maintaining an Outperform rating. This accommodation followed a gathering with the company’s absorption squad to sermon the 2026 nett merchandise gross outlook. Management addressed caller show for Amvuttra, explaining that a brushed November resulted from a fewer one-off factors, which were followed by an awesome December.
jason-briscoe-Gw_sFen8VhU-unsplash
Earlier connected January 12, Needham accrued its terms people for Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) from $520 to $529 with a Buy standing pursuing the company’s Q4 2025 pre-announcement and the merchandise of its 2026 fiscal outlook.
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) discovers, develops, and commercializes therapeutics based connected ribonucleic acerb interference.
While we admit the imaginable of ALNY arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This nonfiction is primitively published at Insider Monkey.

1 week ago
7





English (CA) ·
English (US) ·
Spanish (MX) ·